Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors.
GPCR
adenosine receptor
antagonists
molecular modeling
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
25
09
2023
revised:
24
10
2023
accepted:
30
10
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Adenosine receptors are largely distributed in our organism and are promising therapeutic targets for the treatment of many pathologies. In this perspective, investigating the structural features of the ligands leading to affinity and/or selectivity is of great interest. In this work, we have focused on a small series of pyrazolo-triazolo-pyrimidine antagonists substituted in positions 2, 5, and N8, where bulky acyl moieties at the N5 position and small alkyl groups at the N8 position are associated with affinity and selectivity at the A
Identifiants
pubmed: 38002292
pii: biom13111610
doi: 10.3390/biom13111610
pmc: PMC10669182
pii:
doi:
Substances chimiques
Purinergic P1 Receptor Antagonists
0
Receptors, Purinergic P1
0
Pyrimidines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Chem Inf Model. 2016 Apr 25;56(4):687-705
pubmed: 27019343
Science. 2012 Jul 13;337(6091):232-6
pubmed: 22798613
Trends Pharmacol Sci. 2011 Jan;32(1):35-42
pubmed: 21075459
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Chem Inf Model. 2009 Dec;49(12):2820-36
pubmed: 19908874
Sci Adv. 2022 Dec 23;8(51):eadd3709
pubmed: 36563137
Cells. 2020 Mar 24;9(3):
pubmed: 32213945
Nucleic Acids Res. 2018 Jan 4;46(D1):D440-D446
pubmed: 29155946
Cell. 2017 Feb 23;168(5):867-877.e13
pubmed: 28235198
Nat Rev Drug Discov. 2006 Mar;5(3):247-64
pubmed: 16518376
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9
pubmed: 9459566
J Mol Biol. 2002 Jul 12;320(3):597-608
pubmed: 12096912
J Med Chem. 2002 Jan 3;45(1):115-26
pubmed: 11754583
Proteins. 2004 May 1;55(2):351-67
pubmed: 15048827
J Biol Chem. 2002 May 24;277(21):19056-63
pubmed: 11891221
Cell Discov. 2022 Dec 28;8(1):140
pubmed: 36575181
Front Oncol. 2021 Oct 01;11:679285
pubmed: 34660262
J Biol Chem. 1995 Jun 9;270(23):13987-97
pubmed: 7775460
Biomolecules. 2023 Sep 14;13(9):
pubmed: 37759787
J Med Chem. 2006 Jan 26;49(2):534-53
pubmed: 16420040
Pharmacol Rev. 2022 Apr;74(2):340-372
pubmed: 35302044
J Med Chem. 2000 Dec 14;43(25):4768-80
pubmed: 11123985
Molecules. 2022 Mar 15;27(6):
pubmed: 35335254
Mol Pharmacol. 1982 Jan;21(1):5-16
pubmed: 6982395
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
J Biol Chem. 1985 Nov 25;260(27):14659-64
pubmed: 2997218
Nat Rev Drug Discov. 2013 Apr;12(4):265-86
pubmed: 23535933
Mol Pharmacol. 1984 Jul;26(1):1-9
pubmed: 6087114
Curr Top Med Chem. 2016;16(28):3224-3257
pubmed: 27150365
J Comput Aided Mol Des. 2018 Dec;32(12):1337-1346
pubmed: 30361971
Bioorg Med Chem. 2009 Jul 15;17(14):5259-74
pubmed: 19501513
Trends Biochem Sci. 2014 May;39(5):233-44
pubmed: 24767681
Br J Pharmacol. 2012 Mar;165(6):1688-1703
pubmed: 21864311
Biochem Pharmacol. 2020 Feb;172:113718
pubmed: 31751537
Semin Immunol. 2019 Apr;42:101304
pubmed: 31604539